Gene expression-based risk score in diffuse large B-cell lymphoma. - Inserm - Institut national de la santé et de la recherche médicale Access content directly
Journal Articles Oncotarget Year : 2012

Gene expression-based risk score in diffuse large B-cell lymphoma.


Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma and displays heterogeneous clinical and molecular characteristics. In this study, high throughput gene expression profiling of DLBCL tumor samples was used to design a 12-gene expression-based risk score (GERS) predictive for patient's overall survival. GERS allowed identifying a high-risk group comprising 46,4% of the DLBCL patients in two independent cohorts (n=414 and n=69). GERS was shown to be an independent predictor of survival when compared to the previously published prognostic factors, including the International Prognostic Index (IPI). GERS displayed a prognostic value in germinal-center B-cell-like subgroup (GCB) and activated B cell-like (ABC) molecular subgroups of patients as well as in DLBCL patients treated with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) or Rituximab-CHOP (R-CHOP) regimens. Combination of GERS and IPI lead to a potent prognostic classification of DLBCL patients. Finally, a genomic instability gene signature was highlighted in gene expression profiles of patients belonging to the high-risk GERS-defined group.


Fichier principal
Vignette du fichier
807-7139-6-PBoncotargetdec2012.pdf (1.01 Mo) Télécharger le fichier
Origin : Publisher files allowed on an open archive

Dates and versions

inserm-00802570 , version 1 (20-03-2013)


  • HAL Id : inserm-00802570 , version 1
  • PUBMED : 23482333


Caroline Bret, Bernard Klein, Jérôme Moreaux. Gene expression-based risk score in diffuse large B-cell lymphoma.. Oncotarget, 2012, 3 (12), pp.1700-10. ⟨inserm-00802570⟩
113 View
295 Download



Gmail Facebook X LinkedIn More